A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
06 2020
Historique:
received: 16 03 2020
accepted: 26 03 2020
pubmed: 4 4 2020
medline: 24 6 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. IMPLICATIONS FOR PRACTICE: The main management strategies for treating cancer patients during the COVID-19 epidemic include clear communication and education about hand hygiene, infection control measures, high-risk exposure, and the signs and symptoms of COVID-19. Consideration of risk and benefit for active intervention in the cancer population must be individualized. Postponing elective surgery or adjuvant chemotherapy for cancer patients with low risk of progression should be considered on a case-by-case basis. Minimizing outpatient visits can help to mitigate exposure and possible further transmission. Telemedicine may be used to support patients to minimize number of visits and risk of exposure. More research is needed to better understand SARS-CoV-2 virology and epidemiology.

Identifiants

pubmed: 32243668
doi: 10.1634/theoncologist.2020-0213
pmc: PMC7288661
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e936-e945

Subventions

Organisme : F. Hoffmann-La Roche
Pays : International
Organisme : Khalifa Foundation - Abu Dhabi - United Arab Emirates
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2020 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Références

Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Med J Aust. 2020 Jun;212(10):481-489
pubmed: 32401360
Clin Pharmacol Ther. 2019 Aug;106(2):415-421
pubmed: 30739322
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMC Infect Dis. 2010 Nov 26;10:340
pubmed: 21110854
PLoS One. 2015 Mar 26;10(3):e0120827
pubmed: 25812117
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):292-295
pubmed: 32118394
P T. 2011 Nov;36(11):740-57
pubmed: 22346307
Br J Community Nurs. 2019 Oct 2;24(10):482-484
pubmed: 31604043
J Clin Virol. 2011 Nov;52(3):210-4
pubmed: 21855405
Breast J. 2017 Jul;23(4):444-451
pubmed: 28117507
Clin Infect Dis. 1996 May;22(5):778-82
pubmed: 8722930
Am Soc Clin Oncol Educ Book. 2018 May 23;38:540-545
pubmed: 30231354
Lancet Oncol. 2012 Jun;13(6):579-88
pubmed: 22503032
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
JAMA. 2020 Apr 21;323(15):1439-1440
pubmed: 32163102
Lung Cancer. 2004 Jul;45(1):39-43
pubmed: 15196733
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
Clin Colorectal Cancer. 2017 Sep;16(3):e123-e139
pubmed: 28284574
Br J Haematol. 2016 May;173(3):380-93
pubmed: 27060988
Clin Infect Dis. 2015 Jul 15;61(2):192-202
pubmed: 25847977
J Oncol Pract. 2013 Sep;9(5):e182-5
pubmed: 24045345
N Engl J Med. 2020 Feb 20;382(8):760-762
pubmed: 31978944
Biol Blood Marrow Transplant. 2018 Jul;24(7):1490-1496
pubmed: 29530766
F1000Res. 2014 Sep 12;3:221
pubmed: 25469231
Med Care. 2008 Sep;46(9):991-7
pubmed: 18725855
Breast Cancer Res Treat. 2020 Jun;181(3):487-497
pubmed: 32333293
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Clin Infect Dis. 2013 Jan;56(2):258-66
pubmed: 23024295
Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S344-51
pubmed: 25352629
Open Forum Infect Dis. 2018 May 02;5(5):ofy053
pubmed: 29740593
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
MMWR Recomm Rep. 2004 Mar 26;53(RR-3):1-36
pubmed: 15048056
Australas Radiol. 2003 Jun;47(2):143-5
pubmed: 12780442
Curr Oncol. 2006 Aug;13(4):119-20
pubmed: 17576451
Gastrointest Endosc. 2020 Jul;92(1):192-197
pubmed: 32179106
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Br J Haematol. 2020 Apr;189(2):241-243
pubmed: 32173855
Eur J Cancer. 2015 Nov;51(17):2553-61
pubmed: 26360411
Drugs. 2007;67(10):1411-27
pubmed: 17600390
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Humaid O Al-Shamsi (HO)

Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.
Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Emirates Oncology Society, Dubai, United Arab Emirates.

Waleed Alhazzani (W)

Department of Health Research Methods, Evidence, and Impact, Medicine, McMaster University, Hamilton, Ontario, Canada.
Medicine, McMaster University, Hamilton, Ontario, Canada.

Ahmad Alhuraiji (A)

Department of Hematology, Kuwait Cancer Control Center, Kuwait.

Eric A Coomes (EA)

Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Roy F Chemaly (RF)

Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Meshari Almuhanna (M)

Min-Sheng General Hospital, Taoyuan City, Taiwan.

Robert A Wolff (RA)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Nuhad K Ibrahim (NK)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Melvin L K Chua (MLK)

Divisions of Radiation Oncology and Medical Sciences, National Cancer Center Singapore, Singapore.
Oncology Academic Program, Duke-NUS Medical School, Singapore.
Cong Hua's Institute, Singapore.

Sebastien J Hotte (SJ)

Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.

Brandon M Meyers (BM)

Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.

Tarek Elfiki (T)

Windsor Regional Cancer Center, Windsor, Ontario, Canada.
Department of Oncology, Schulich School of Medicine, University of Western Ontario, London, Ontario, Canada.

Giuseppe Curigliano (G)

Department of Oncology and Hemato-Oncology University of Milan, Milan, Italy.
Division of Early Drug Development for Innovative Therapy, University of Milan, Milan, Italy.
European Institute of Oncology, Milan, Italy.
IRCCS, University of Milano, Milan, Italy.

Cathy Eng (C)

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.

Axel Grothey (A)

West Cancer Center, University of Tennessee, Memphis, Tennessee, USA.

Conghua Xie (C)

Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH